

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/556,227	First Named Inventor: Laurent David
371 Filing Date: November 9, 2005	Attorney Docket No.: 101055-1P US
Examiner: Patricia L. Morris	Group Art Unit: 1625
Customer No.: 44992	Confirmation No.: 4286
Title: Azaindole Compounds as Kinase Inhibitors	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Response to Restriction Requirement

Sir:

This paper is being filed in response to the Requirement for Restriction mailed on September 27, 2007. This paper is being filed with a Request for a One-Month Extension of Time.

Remarks

The Examiner has required restriction among two groups of allegedly distinct inventions:

- I. Claims 12-17, 19, and 22, drawn to compounds and process; and
- II. Claims 20 and 21, drawn to multiple uses.

Applicants hereby elect Group I: Claims 12-17, 19, and 22, drawn to compounds and process.

Applicants elect 4-(2-Ethyl-phenylamino)-2-(4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid amide as a single compound, and elect asthma as a specific disease.

The above remarks have been made without prejudice to Applicants' right to prosecute any withdrawn subject matter in a timely filed continuing application.

Respectfully submitted,
/John X. Haberman/

Name: John X. Haberman
Dated: November 6, 2007
Reg. No.: 55,236
Phone No.: 781-839-4736
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451